OncoMatch/Clinical Trials/NCT03422731
Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy
Is NCT03422731 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies Fluorothymidine F-18 for acute lymphoblastic leukemia.
Treatment: Fluorothymidine F-18 — This clinical trial investigates multi-modality imaging and collection of biospecimen samples in understanding bone marrow changes in patients with acute myeloid leukemia undergoing total body irradiation (TBI) and chemotherapy. Using multi-modality imaging and collecting biospecimen samples may help doctors know more about how TBI and chemotherapy can change the bone marrow.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Disease stage
Required: Stage FIRST REMISSION, SECOND REMISSION
First or second remission AML or ALL patients
Prior therapy
Cannot have received: stem cell transplant
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Medical Center · Duarte, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify